OverviewChartTechnicalNews
Derivatives
TraderScreen

Genfit SA/  FR0004163111  /

Euronext - Paris
2024-10-18  5:35:14 PM Chg. -0.370 Volume Bid5:40:00 PM Ask5:40:00 PM High Low
5.330EUR -6.49% 575,710
Turnover: 3.18 mill.		 5.300Bid Size: 500 5.500Ask Size: 436 5.750 5.220
GlobeNewswire 07-26 GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cho...
GlobeNewswire 07-26 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire 06-17 GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Det...
GlobeNewswire 06-10 GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primar...
GlobeNewswire 06-10 Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...
GlobeNewswire 05-29 GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
GlobeNewswire 05-22 GENFIT: May 22, 2024 Combined Shareholders Meeting Results
GlobeNewswire 05-14 GENFIT Reports First Quarter 2024 Financial Information
GlobeNewswire 04-25 GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
GlobeNewswire 04-15 GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
GlobeNewswire 04-05 GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report ...
GlobeNewswire 04-04 GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 02-29 GENFIT Announces Revenues and Cash Position as of December 31, 2023
GlobeNewswire 01-15 GENFIT Announces 2024 Financial Calendar  
GlobeNewswire 2023-12-08 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangit...
GlobeNewswire 2023-12-07 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 2023-12-07 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 2023-12-06 GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a...
GlobeNewswire 2023-11-16 GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
GlobeNewswire 2023-11-13 Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire 2023-11-13 GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as lat...
GlobeNewswire 2023-11-09 GENFIT Reports Third Quarter 2023 Financial Information
GlobeNewswire 2023-11-02 GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
GlobeNewswire 2023-09-26 GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Te...
GlobeNewswire 2023-09-20 GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update